Table 2. Gene mutation frequency according to the efficacy group of patients taking crizotinib.
| Gene analyzed | Good, n (%) (n=13) | Intermediate, n (%) (n=17) | Poor, n (%) (n=6) | P value* |
|---|---|---|---|---|
| TP53 | 0.625 | |||
| Mutant | 5 (38.5) | 5 (29.4) | 1 (16.7) | |
| Wild type | 8 (61.5) | 12 (70.6) | 5 (83.3) | |
| FAT3 | 0.450 | |||
| Mutant | 3 (23.1) | 3 (17.6) | 0 (0) | |
| Wild type | 10 (76.9) | 14 (82.4) | 6 (100.0) | |
| SMARCA4 | 0.607 | |||
| Mutant | 2 (15.4) | 2 (11.8) | 0 (0) | |
| Wild type | 11 (84.6) | 15 (88.2) | 6 (100.0) | |
| BRCA2 | 0.665 | |||
| Mutant | 1 (7.7) | 2 (11.8) | 0 (0) | |
| Wild type | 12 (92.3) | 15 (88.2) | 6 (100.0) | |
| RUNX1 | 0.304 | |||
| Mutant | 1 (7.7) | 2 (11.8) | 2 (33.3) | |
| Wild type | 12 (92.3) | 15 (88.2) | 4 (66.7) | |
| SETD2 | 0.161 | |||
| Mutant | 0 (0) | 3 (17.6) | 0 (0) | |
| Wild type | 13 (100.0) | 14 (82.4) | 6 (100.0) | |
| SPEN | 0.720 | |||
| Mutant | 1 (7.7) | 3 (17.6) | 1 (16.7) | |
| Wild type | 12 (92.3) | 14 (82.4) | 5 (83.3) | |
| EGFR 19del | 0.791 | |||
| Mutant | 1 (7.7) | 1 (5.9) | 0 (0) | |
| Wild type | 12 (92.3) | 16 (94.1) | 6 (100.0) | |
| EGFR L858R | 0.076 | |||
| Mutant | 0 (0) | 0 (0) | 1 (16.7) | |
| Wild type | 13 (100.0) | 17 (100.0) | 5 (83.3) | |
| BRAF V600E | 0.076 | |||
| Mutant | 0 (0) | 0 (0) | 1 (16.7) | |
| Wild type | 13 (100.0) | 17 (100.0) | 5 (83.3) |
*, chi-square test.